July 2013

In 2009, Marco Tuccori, PharroD, et al. published a report titled “Safety Concerns Associated With the Use of Serotonin Reuptake Inhibitors and Other Serotonergic/Noradrenergic Antidepressants During Pregnancy: A Review” in Clinical Therapeutics that establishes reason to believe certain SSRI medications are unsafe for a developing fetus.

Once proper consent was obtained, the Tuccori et

A 2007 review published in Pharmacotherapy analyzed the effects of several common antidepressant medications during pregnancy and concluded that “Third-trimester exposure to newer antidepressants, including SSRIs and serotonin-norepinephrine reuptake inhibitors (e.g., venlafaxine), has been associated with a poor neonatal adaptation syndrome. In addition, SSRI use may be associated with an increased risk of persistent pulmonary

Pelvic organ prolapse is a condition which has been swarmed with controversy as all reparatory methods haven’t led to a sufficiently-high success rate to allow for continued use.  As medical science advances, there have been a range of methods for attempting to solve the issues caused by pelvic organ prolapse, and currently, the use of

Venlafaxine (Effexor) has become a popular antidepressant medication, used to treat major depression and anxiety disorders in adults.  The antidepressant has been widely used, seen as a highly effective medication for patients across a broad demographic.  A current study conducted by Kara Polen, et. al. concerned itself with the lack of research done on Venlafaxine’s

With the increased use of transvaginal mesh kits in the repair of pelvic organ prolapse, there has been a rising controversy to the safety of such products.  It is often observed that the these relatively-new products are not properly tested to determine their safety, and with the ever increasing number of new versions of transvaginal